RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VBI Vaccines - Stock

VBI Vaccines ROE 2024

VBI Vaccines ROE

-12.47

Ticker

VBIV

ISIN

CA91822J1030

WKN

A2AJ0L

In 2024, VBI Vaccines's return on equity (ROE) was -12.47, a 606.44% increase from the -1.76 ROE in the previous year.

VBI Vaccines Aktienanalyse

What does VBI Vaccines do?

VBI Vaccines Inc is a company focused on the development and commercialization of vaccines. The company was founded in Canada in 2001 and is currently headquartered in Cambridge, Massachusetts, USA. Its business model is based on research, development, and marketing of vaccines for the prevention and treatment of infectious diseases. VBI Vaccines works closely with academic institutions, government agencies, biotech companies, and pharmaceutical companies to advance its products. The company offers a wide range of products, including prophylactic vaccines against infectious diseases such as Hepatitis B, Cytomegalovirus, Japanese encephalitis, and uncontrolled HIV infections. It is also working on the development of therapeutic vaccines against cancer. One of VBI Vaccines' key divisions is the hepatitis B vaccines, with its innovative platform called Sci-B-Vac offering higher protection and longer effectiveness than other available vaccines. VBI Vaccines has also developed a prophylactic platform called LPV™ technology (Lipid Particle Vaccine) which facilitates vaccine production by being easy to manufacture, stable, and transportable. This technology also allows for rapid development of vaccines against new infectious diseases. The company is also involved in the clinical development of therapeutic vaccines against cancer, aiming to mobilize and activate the body's immune system against cancer cells. Successful clinical studies have been conducted for therapy vaccines against glioblastomas (a type of brain tumor) and rhabdomyosarcomas (a rare tumor). Overall, VBI Vaccines has a promising research path for the development of vaccines for the prevention and treatment of infectious diseases and cancer. The company is innovative and relies on technologies that improve vaccine effectiveness and ease their production. VBI Vaccines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding VBI Vaccines's Return on Equity (ROE)

VBI Vaccines's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing VBI Vaccines's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

VBI Vaccines's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in VBI Vaccines’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about VBI Vaccines Stock

What is the ROE (Return on Equity) of VBI Vaccines this year?

The ROE of VBI Vaccines this year is -12.47 undefined.

How has the Return on Equity (ROE) of VBI Vaccines developed compared to the previous year?

The ROE of VBI Vaccines has increased by 606.44% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of VBI Vaccines?

A high ROE indicates that VBI Vaccines generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of VBI Vaccines?

A low ROE can indicate that VBI Vaccines is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of VBI Vaccines affect the company?

A change in ROE (Return on Equity) of VBI Vaccines can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of VBI Vaccines?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of VBI Vaccines?

Some factors that can influence VBI Vaccines's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does VBI Vaccines pay?

Over the past 12 months, VBI Vaccines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VBI Vaccines is expected to pay a dividend of 0 USD.

What is the dividend yield of VBI Vaccines?

The current dividend yield of VBI Vaccines is .

When does VBI Vaccines pay dividends?

VBI Vaccines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VBI Vaccines?

VBI Vaccines paid dividends every year for the past 0 years.

What is the dividend of VBI Vaccines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VBI Vaccines located?

VBI Vaccines is assigned to the 'Health' sector.

Wann musste ich die Aktien von VBI Vaccines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VBI Vaccines from 6/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/21/2024.

When did VBI Vaccines pay the last dividend?

The last dividend was paid out on 6/21/2024.

What was the dividend of VBI Vaccines in the year 2023?

In the year 2023, VBI Vaccines distributed 0 USD as dividends.

In which currency does VBI Vaccines pay out the dividend?

The dividends of VBI Vaccines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VBI Vaccines

Our stock analysis for VBI Vaccines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VBI Vaccines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.